Derek Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Derek Cheng has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- David A. Tuveson
Cold spring harbor laboratory, cold spring harbor, USA
3 shared publications - Brinda Alagesan
Memorial Sloan Kettering Cancer Center 1 Department of Medicine New York, New York
2 shared publications - Darryl J. C. Pappin
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA
2 shared publications - Jennifer S. Thalappillil
Dana-Farber Cancer Institute 1 Department of Medical Oncology Harvard Medical School, Boston, Massachusetts
2 shared publications - Keith D. Rivera
Cold spring harbor laboratory, cold spring harbor, USA
2 shared publications - Linda Van Aelst
Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, USA
2 shared publications
Latest Publications
- Open Access
- 21 May 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (21)
Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with limited treatment options. Although activating mutations of the KRAS GTPase are the predominant dependency present in >90% of PDAC patients, targeting KRAS mutants directly has been challenging in PDAC. Similarly, strategies targeting known KRAS downstream effectors have had limited clinical success due to feedback mechanisms, alternate pathways, and dose-limiting toxicities in normal tissues. Therefore, identifying additional functionally relevant KRAS interactions in PDAC may allow for a better understanding of feedback mechanisms and unveil potential therapeutic targets. Here, we used proximity labeling to identify protein interactors of active KRAS in PDAC cells. We expressed fusions of wild-type (WT) (BirA-KRAS4B), mutant (BirA-KRAS4BG12D), and nontransforming cytosolic double mutant (BirA-KRAS4BG12D/C185S) KRAS with the BirA biotin ligase in murine PDAC cells. Mass spectrometry analysis revealed that RSK1 selectively interacts with membrane-bound KRASG12D, and we demonstrate that this interaction requires NF1 and SPRED2. We find that membrane RSK1 mediates negative feedback on WT RAS signaling and impedes the proliferation of pancreatic cancer cells upon the ablation of mutant KRAS. Our findings link NF1 to the membrane-localized functions of RSK1 and highlight a role for WT RAS signaling in promoting adaptive resistance to mutant KRAS-specific inhibitors in PDAC. Significance For decades, KRAS interactors have been sought after as potential therapeutic targets in KRAS mutant cancers, especially pancreatic ductal adenocarcinoma (PDAC). Our proximity labeling screen with KRAS in PDAC cells highlights RSK1 as a notable mutant-specific interactor. Functionally, we show that RSK1 mediates negative feedback on wild-type (WT) KRAS in PDAC cells. Targeting oncogenic KRAS eliminates the negative feedback on WT RAS and highlights a role for WT RAS signaling in promoting adaptive resistance to mutant KRAS ablation.
- 21 May 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (21)
Open AccessOncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with limited treatment options. Although activating mutations of the KRAS GTPase are the predominant dependency present in >90% of PDAC patients, targeting KRAS mutants directly has been challenging in PDAC. Similarly, strategies targeting known KRAS downstream effectors have had limited clinical success due to feedback mechanisms, alternate pathways, and dose-limiting toxicities in normal tissues. Therefore, identifying additional functionally relevant KRAS interactions in PDAC may allow for a better understanding of feedback mechanisms and unveil potential therapeutic targets. Here, we used proximity labeling to identify protein interactors of active KRAS in PDAC cells. We expressed fusions of wild-type (WT) (BirA-KRAS4B), mutant (BirA-KRAS4BG12D), and nontransforming cytosolic double mutant (BirA-KRAS4BG12D/C185S) KRAS with the BirA biotin ligase in murine PDAC cells. Mass spectrometry analysis revealed that RSK1 selectively interacts with membrane-bound KRASG12D, and we demonstrate that this interaction requires NF1 and SPRED2. We find that membrane RSK1 mediates negative feedback on WT RAS signaling and impedes the proliferation of pancreatic cancer cells upon the ablation of mutant KRAS. Our findings link NF1 to the membrane-localized functions of RSK1 and highlight a role for WT RAS signaling in promoting adaptive resistance to mutant KRAS-specific inhibitors in PDAC. Significance For decades, KRAS interactors have been sought after as potential therapeutic targets in KRAS mutant cancers, especially pancreatic ductal adenocarcinoma (PDAC). Our proximity labeling screen with KRAS in PDAC cells highlights RSK1 as a notable mutant-specific interactor. Functionally, we show that RSK1 mediates negative feedback on wild-type (WT) KRAS in PDAC cells. Targeting oncogenic KRAS eliminates the negative feedback on WT RAS and highlights a role for WT RAS signaling in promoting adaptive resistance to mutant KRAS ablation.
- Open Access
Oncogenic KRAS engages an RSK1/NF1 complex in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with limited treatment options. Although activating mutations of the KRAS GTPase are the predominant dependency present in >90% of PDAC patients, targeting KRAS mutants directly has been challenging in PDAC. Similarly, strategies targeting known KRAS downstream effectors have had limited clinical success due to feedback mechanisms, alternate pathways and toxicity due to the targeting of normal tissues. Therefore, identifying additional functionally relevant KRAS interactions in PDAC may allow for a better understanding of feedback mechanisms and unveil new potential therapeutic targets. Here, we used proximity labelling to identify protein interactors of active KRAS in PDAC cells. Fusions of wildtype (BirA-KRAS4B), mutant (BirA-KRAS4B G12D ) and non-transforming and cytosolic double mutant (BirA-KRAS4B G12D/C185S ) KRAS with the BirA biotin ligase were expressed in murine PDAC cells. Mass spectrometry analysis revealed that RSK1 was enriched among proteins that selectively interacted with membrane-bound KRAS G12D . RSK1 required the NF1 and SPRED proteins to interact with KRAS-GTP at the membrane. In both murine and human PDAC lines, membrane-targeted RSK1 was tolerated but inhibited cell proliferation following oncogenic KRAS abrogation to reveal a negative feedback role for membrane-localized RSK1 on wild-type KRAS. Inhibition of the wild-type KRAS, which has been previously proposed to suppress KRAS oncogenesis, may partially explain how RSK1 has been identified as a dependency in some KRAS mutant cells and may provide an additional function for NF1 in tumorigenesis. Significance Statement: For decades, KRAS interactors have been sought after as potential therapeutic targets in KRAS mutant cancers, especially pancreatic adenocarcinoma (PDAC). Our proximity labeling screen with KRAS in PDAC cells highlight RSK1 as a notable mutant-specific interactor. Functionally, we show that RSK1 mediates negative feedback on wild-type KRAS in PDAC cells.
Open AccessOncogenic KRAS engages an RSK1/NF1 complex in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with limited treatment options. Although activating mutations of the KRAS GTPase are the predominant dependency present in >90% of PDAC patients, targeting KRAS mutants directly has been challenging in PDAC. Similarly, strategies targeting known KRAS downstream effectors have had limited clinical success due to feedback mechanisms, alternate pathways and toxicity due to the targeting of normal tissues. Therefore, identifying additional functionally relevant KRAS interactions in PDAC may allow for a better understanding of feedback mechanisms and unveil new potential therapeutic targets. Here, we used proximity labelling to identify protein interactors of active KRAS in PDAC cells. Fusions of wildtype (BirA-KRAS4B), mutant (BirA-KRAS4B G12D ) and non-transforming and cytosolic double mutant (BirA-KRAS4B G12D/C185S ) KRAS with the BirA biotin ligase were expressed in murine PDAC cells. Mass spectrometry analysis revealed that RSK1 was enriched among proteins that selectively interacted with membrane-bound KRAS G12D . RSK1 required the NF1 and SPRED proteins to interact with KRAS-GTP at the membrane. In both murine and human PDAC lines, membrane-targeted RSK1 was tolerated but inhibited cell proliferation following oncogenic KRAS abrogation to reveal a negative feedback role for membrane-localized RSK1 on wild-type KRAS. Inhibition of the wild-type KRAS, which has been previously proposed to suppress KRAS oncogenesis, may partially explain how RSK1 has been identified as a dependency in some KRAS mutant cells and may provide an additional function for NF1 in tumorigenesis. Significance Statement: For decades, KRAS interactors have been sought after as potential therapeutic targets in KRAS mutant cancers, especially pancreatic adenocarcinoma (PDAC). Our proximity labeling screen with KRAS in PDAC cells highlight RSK1 as a notable mutant-specific interactor. Functionally, we show that RSK1 mediates negative feedback on wild-type KRAS in PDAC cells.
- 8 January 2018
- Published by Cold Spring Harbor Laboratory in Cold Spring Harbor Perspectives in Medicine
- Vol. 8 (10) , a031575
Kras in Organoids
Oncogenic Kras are genetic dependencies for the majority of pancreatic and colorectal adenocarcinomas; however, much remains to be understood regarding its tropism to these carcinomas. Recently developed organoid technology presents a more representative model culture system for pancreatic and colon epithelial tissues as well as better fostering the culture of nonimmortalized cells than two-dimensional culture. These advantages enable cancer researchers to directly compare tumor and normal tissue models to better study tumor initiation as well as therapeutic efficacy. Although in vivo models better model the complexity of multiple cell types, the organoid system allows for easier genetic manipulations and isolation of specific cell types. Furthermore, syngeneic orthotopically transplanted organoids recapitulate tumor histologically and gene expression of the tumors from which they were derived. Thus, organoids may extend the use of genetically engineered mouse models. These advantages of organoid cultures allow for many questions, including but not limited to studying the interaction between different cell types within a tumor and elucidating dependencies of Kras-driven tumors.
- 8 January 2018
- Published by Cold Spring Harbor Laboratory in Cold Spring Harbor Perspectives in Medicine
- Vol. 8 (10) , a031575
Kras in Organoids
Oncogenic Kras are genetic dependencies for the majority of pancreatic and colorectal adenocarcinomas; however, much remains to be understood regarding its tropism to these carcinomas. Recently developed organoid technology presents a more representative model culture system for pancreatic and colon epithelial tissues as well as better fostering the culture of nonimmortalized cells than two-dimensional culture. These advantages enable cancer researchers to directly compare tumor and normal tissue models to better study tumor initiation as well as therapeutic efficacy. Although in vivo models better model the complexity of multiple cell types, the organoid system allows for easier genetic manipulations and isolation of specific cell types. Furthermore, syngeneic orthotopically transplanted organoids recapitulate tumor histologically and gene expression of the tumors from which they were derived. Thus, organoids may extend the use of genetically engineered mouse models. These advantages of organoid cultures allow for many questions, including but not limited to studying the interaction between different cell types within a tumor and elucidating dependencies of Kras-driven tumors.
- 28 July 2011
- Published by Wiley in Advanced Materials
- Vol. 23 (34) , 3954-3958
Permanent Polarity and Piezoelectricity of Electrospun α‐Helical Poly(α‐Amino Acid) Fibers
- 28 July 2011
- Published by Wiley in Advanced Materials
- Vol. 23 (34) , 3954-3958
Permanent Polarity and Piezoelectricity of Electrospun α‐Helical Poly(α‐Amino Acid) Fibers
- 7 June 2010
- Published by Royal Society of Chemistry (RSC) in Soft Matter
- Vol. 6 (15) , 3596-3608
Responsive microcapsule reactors based on hydrogen-bonded tannic acid layer-by-layer assemblies
We explore responsive properties of hollow multilayer shells of tannic acid assembled with a range of neutral polymers, poly(N-vinylpyrrolidone) (PVPON), poly(N-vinylcaprolactam) (PVCL) or poly(N-isopropylacrylamide) (PNIPAM). We found that properties of the nanoscale shells fabricated through hydrogen-bonded layer-by-layer (LbL) assembly can be tuned changing the interaction strength of a neutral polymer with tannic acid, and by a change in counterpart hydrophobicity. Unlike most hydrogen-bonded LbL films with two polymer components, the produced tannic acid-based multilayer shells are extremely stable in the wide pH range from 2 to 10. We demonstrate that gold nanoparticles can be grown within tannic acid-containing shell walls under mild environmental conditions paving the way for further modification of the capsule walls through thiol-based surface chemistry. Moreover, these shells show reversible pH-triggered changes in surface charge and permeability towards FITC-labeled polysaccharide molecules. The permeability of these LbL containers can be controlled by changing pH providing an opportunity for loading and release of a functional cargo under mild conditions.
- 7 June 2010
- Published by Royal Society of Chemistry (RSC) in Soft Matter
- Vol. 6 (15) , 3596-3608
Responsive microcapsule reactors based on hydrogen-bonded tannic acid layer-by-layer assemblies
We explore responsive properties of hollow multilayer shells of tannic acid assembled with a range of neutral polymers, poly(N-vinylpyrrolidone) (PVPON), poly(N-vinylcaprolactam) (PVCL) or poly(N-isopropylacrylamide) (PNIPAM). We found that properties of the nanoscale shells fabricated through hydrogen-bonded layer-by-layer (LbL) assembly can be tuned changing the interaction strength of a neutral polymer with tannic acid, and by a change in counterpart hydrophobicity. Unlike most hydrogen-bonded LbL films with two polymer components, the produced tannic acid-based multilayer shells are extremely stable in the wide pH range from 2 to 10. We demonstrate that gold nanoparticles can be grown within tannic acid-containing shell walls under mild environmental conditions paving the way for further modification of the capsule walls through thiol-based surface chemistry. Moreover, these shells show reversible pH-triggered changes in surface charge and permeability towards FITC-labeled polysaccharide molecules. The permeability of these LbL containers can be controlled by changing pH providing an opportunity for loading and release of a functional cargo under mild conditions.